Dowden Nathan J — SEC insider filings
SEC reporting owner CIK 1873392. 29 insider filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 29 filings on record, filed 2021-11-01 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 31 legs across 17 filings — 119,090 shares, $1,900,231 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 37.
- Largest priced transaction: sale of 26,595 shares @ $16.26 ($432,419) in Entrada Therapeutics, Inc., filed 2024-08-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | President & COO | 29 | — | 31 legs · 119,090 sh · $1,900,231 | 37 |
Insider filings — Dowden Nathan J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 2,528 @ $7.14 | EDGAR |
| 2026-05-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Option exercise (M): 15,000 @ $1.74 · Sale (S): 15,000 @ $15.33 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,116 @ $13.02 · Sale (S): 11,894 @ $13.05 | EDGAR |
| 2026-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 55,800 @ $0 · Tax withholding (F): 7,223 @ $11.66 · Tax withholding (F): 14,038 @ $11.76 · Grant/award (A): 83,200 (derivative) @ $0 | EDGAR |
| 2025-09-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 1,746 @ $5.43 | EDGAR |
| 2025-03-04 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 60,800 @ $0 · Tax withholding (F): 5,144 @ $11.68 · Grant/award (A): 90,800 (derivative) @ $0 | EDGAR |
| 2024-09-30 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 847 @ $16 | EDGAR |
| 2024-09-10 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 399 @ $15.19 · Sale (S): 1,904 @ $15.07 | EDGAR |
| 2024-09-05 | 4 | Entrada Therapeutics, Inc. (TRDA) | Tax withholding (F): 483 @ $15.76 · Tax withholding (F): 156 @ $16.93 · Tax withholding (F): 15 @ $17.70 · Tax withholding (F): 983 @ $15.42 · Tax withholding (F): 171 @ $15.13 | EDGAR |
| 2024-08-20 | 4 | Entrada Therapeutics, Inc. (TRDA) | Option exercise (M): 20,000 @ $1.74 · Sale (S): 26,595 @ $16.26 · Sale (S): 502 @ $16.70 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,826 @ $12.32 | EDGAR |
| 2024-03-05 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 33,100 @ $0 · Grant/award (A): 60,000 @ $0 · Tax withholding (F): 343 @ $12.42 · Tax withholding (F): 409 @ $13.37 · Tax withholding (F): 1,486 @ $12.28 · Grant/award (A): 50,100 (derivative) @ $0 | EDGAR |
| 2023-09-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 14,200 @ $0 · Tax withholding (F): 436 @ $14.46 · Sale (S): 913 @ $13.43 · Sale (S): 59 @ $14.01 · Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2023-07-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,200 @ $18.00 · Sale (S): 3,897 @ $18.05 | EDGAR |
| 2023-06-22 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 8,885 @ $14.94 · Sale (S): 7,097 @ $16.02 | EDGAR |
| 2023-04-19 | 4/A | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 14,200 @ $0 · Grant/award (A): 21,500 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 28,400 @ $0 · Tax withholding (F): 1,028 @ $11.60 · Grant/award (A): 43,000 (derivative) @ $0 | EDGAR |
| 2022-11-02 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 2,100 @ $24.05 | EDGAR |
| 2022-10-27 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,034 @ $20.10 · Sale (S): 5,414 @ $20.97 · Sale (S): 900 @ $21.85 | EDGAR |
| 2022-10-24 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 905 @ $18.07 · Sale (S): 2,771 @ $18.29 · Sale (S): 1,102 @ $18.88 · Sale (S): 1,302 @ $19.66 | EDGAR |
| 2022-09-28 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 1,329 @ $15.32 · Sale (S): 215 @ $16.25 | EDGAR |
| 2022-09-23 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 3,275 @ $15.13 · Sale (S): 1,018 @ $15.07 | EDGAR |
| 2022-09-19 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 100 @ $15.01 | EDGAR |
| 2022-09-12 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 912 @ $15.15 · Sale (S): 865 @ $15.06 | EDGAR |
| 2022-09-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 5,632 @ $0 | EDGAR |
| 2022-07-06 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 33,788 (derivative) @ $0 | EDGAR |
| 2022-06-29 | 4 | Entrada Therapeutics, Inc. (TRDA) | Sale (S): 7,714 @ $13 | EDGAR |
| 2022-03-03 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 11,263 @ $0 · Grant/award (A): 67,575 (derivative) @ $0 | EDGAR |
| 2021-11-01 | 4 | Entrada Therapeutics, Inc. (TRDA) | Grant/award (A): 95,148 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-10-27 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1873392 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs